|開催日時：||2019年12月4日 １3：00 ～ １4：00|
|開催場所：||４号館３階 国際粘膜ワクチン開発研究センター セミナー室|
|演題：||For the development of vaccines against infectious diseases|
Vaccines are highly effective at preventing infectious diseases. With continued development of immunological innovations, such as check point therapy for cancer, vaccines likely will become useful therapeutic tools against cancer. The various types of vaccines against infectious diseases include live attenuated vaccines, inactivated whole vaccines, and protein- or peptide-based subunit vaccines. They all have various advantages and disadvantages. For example, subunit vaccines are much safer than live attenuated vaccines and inactivated whole vaccines; however, when used alone, subunit vaccines evoke only weak adaptive immunity. Adaptive immune responses are initiated and regulated by dendritic cells, which acquire antigens and present them to B and T lymphocytes. Therefore, to enhance adaptive immune responses in subunit vaccines, delivering vaccine antigens to dendritic cells with appropriate adjuvants is an attractive approach. In addition, it is important to discover and design optimal vaccine antigens from pathogens. In this presentation, I would like to discuss my recent research for the development of subunit vaccines about 1) dendritic cell-targeting peptide as a vehicle for vaccine antigens, 2) cellular surface receptor of oligonucleotides-based adjuvants for designing novel adjuvants, 3) optimal use of adjuvants for influenza virus vaccine and 4) development of vaccine against Mycoplasma pneumoniae.